Up-regulation of early growth response gene 1 (EGR-1) via ERK1/2 signals attenuates sulindac sulfide-mediated cytotoxicity in the human intestinal epithelial cells

被引:24
作者
Moon, Yuseok [1 ]
Yang, Hyun [1 ]
Kim, Yung Bu [1 ]
机构
[1] Pusan Natl Univ, Sch Med, Med Res Inst, Dept Microbiol & Immunol, Pusan 602739, South Korea
基金
新加坡国家研究基金会;
关键词
EGR-1; NSAID; ERK1/2 MAP kinase; apoptosis; intestinal epithelial cells; ulcer;
D O I
10.1016/j.taap.2007.04.018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Non-steroidal anti-inflammatory drugs (NSAIDs) are used to relieve pain and inflammation and have also received considerable attention because of their preventive effects against human cancer. However, the drug application is sometimes limited by the severe gastrointestinal ulcers and mucosal complications. In the present study, NSAID sulindac sulfide was investigated for the cytotoxic injury in the intestinal epithelial cells in association with an immediate inducible factor, early growth response gene 1 (EGR-1). Previously we reported that sulindac sulfide can suppress tumor cell invasion by inducing EGR-1. Extending the previous study, EGR-1 induction by sulindac sulfide was observed both in the non-transformed and transformed human intestinal epithelial cell lines. In terms of signaling pathway, ERK1/2 MAP kinases and its substrate Elk-1 transcription factor were involved in the sulindac sulfide-induced EGR-1 gene expression. Moreover, sulindac sulfide stimulated the nuclear translocation of the transcription factor EGR-1, which was also mediated by ERK1/2 signaling pathway. The roles of EGR-1 signals in the apoptotic cell death were assessed in the intestinal epithelial cells. Suppression of EGR-1 expression retarded cellular growth and colony forming activity in the intestinal epithelial cells. Moreover, induced EGR-1 ameliorated sulindac sulfide-mediated apoptotic cell death and enhanced the cellular survival. Taken all together, sulindac sulfide activated ERK1/2 MAP kinases which then mediated EGR-1 induction and nuclear translocation. all of which played important roles in the cellular survival from NSAID-mediated cytotoxicity in the human intestinal epithelial cells, implicating the protective roles of EGR-1 in the NSAID-mediated mucosal injuries. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:155 / 163
页数:9
相关论文
共 37 条
[1]   Helicobacter pylori activates the early growth response 1 protein in gastric epithelial cells [J].
Abdel-Latif, MMM ;
Windle, HJ ;
Fitzgerald, KA ;
Ang, YS ;
Eidhin, DN ;
Li-Weber, M ;
Sabra, K ;
Kelleher, D .
INFECTION AND IMMUNITY, 2004, 72 (06) :3549-3560
[2]   Impaired prostate tumorigenesis in Egr1-deficient mice [J].
Abdulkadir, SA ;
Qu, ZC ;
Garabedian, E ;
Song, SK ;
Peters, TJ ;
Svaren, J ;
Carbone, JM ;
Naughton, CK ;
Catalona, WJ ;
Ackerman, JJH ;
Gordon, JI ;
Humphrey, PA ;
Milbrandt, J .
NATURE MEDICINE, 2001, 7 (01) :101-107
[3]  
[Anonymous], 1998, REV BUSINESS
[4]   Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein [J].
Baek, SJ ;
Kim, JS ;
Moore, SM ;
Lee, SH ;
Martinez, J ;
Eling, TE .
MOLECULAR PHARMACOLOGY, 2005, 67 (02) :356-364
[5]   Troglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) ligand, selectively induces the early growth response-1 gene independently of PPARγ -: A novel mechanism for its anti-tumorigenic activity [J].
Baek, SJ ;
Wilson, LC ;
Hsi, LC ;
Eling, TE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (08) :5845-5853
[6]   Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo [J].
Baron, V ;
De Gregorio, G ;
Krones-Herzig, A ;
Virolle, T ;
Calogero, A ;
Urcis, R ;
Mercola, D .
ONCOGENE, 2003, 22 (27) :4194-4204
[7]   The transcription factor Egr-1: a potential drug in wound healing and tissue repair [J].
Braddock, M .
ANNALS OF MEDICINE, 2001, 33 (05) :313-318
[8]   COX-2: A molecular target for colorectal cancer prevention [J].
Brown, JR ;
DuBois, RN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) :2840-2855
[9]   Primer: managing NSAID-induced ulcer complications-balancing gastrointestinal and cardiovascular risks [J].
Chan, Francis K. L. .
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2006, 3 (10) :563-573
[10]  
Davies NM, 1999, J PHARM PHARM SCI, V2, P5